How have VRP shares performed in 2024?

Verona Pharma plc (VRP.L)'s stock was trading at GBX 55 at the beginning of 2024. Since then, VRP shares have increased by 0.0% and is now trading at GBX 55. View the best growth stocks for 2024 here .

How were Verona Pharma plc (VRP.L)'s earnings last quarter?

Verona Pharma plc (VRP.L) (LON:VRP) posted its quarterly earnings data on Thursday, February, 27th. The company reported ($30.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($30.80) by $0.50.

What other stocks do shareholders of Verona Pharma plc (VRP.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verona Pharma plc (VRP.L) investors own include Verona Pharma (VRNA) , Fate Therapeutics (FATE) , Pluristem Therapeutics (PSTI) , AbbVie (ABBV) , BioMarin Pharmaceutical (BMRN) , Exelixis (EXEL) , Amicus Therapeutics (FOLD) , Global Blood Therapeutics (GBT) , Grifols (GRFS) and Innoviva (INVA) .

How do I buy shares of Verona Pharma plc (VRP.L)?

Shares of VRP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. Compare Top Brokerages Here .

LON:VRP

Verona Pharma plc (VRP.L) (VRP) Share Price, News & Analysis

→ A new way to collect income from stocks (From DTI) (Ad)

Free VRP Stock Alerts

GBX 55

+3.00 (+5.77%)

(As of 10/29/2020)

Today's Range: 50
▼
56
50-Day Range: 55
▼
55
52-Week Range: 28.60
▼
115

Volume: 70,791 shs
Average Volume: 150,610 shs
Market Capitalization: £228.00 million

Assets Under Management: N/A
Dividend Yield: N/A
Net Expense Ratio: 0.00%

Stock Analysis

Get Verona Pharma plc (VRP.L) alerts:

About Verona Pharma plc (VRP.L) (LON:VRP)

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and II clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, chronic asthma, and allergic rhinitis. Verona Pharma plc was founded in 2005 and is headquartered in London, the United Kingdom.

VRP Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VRP ETF News Headlines

April 9, 2024 | americanbankingnews.com

Verona Pharma plc (VRP.L) (LON:VRP) Stock Price Passes Below 200 Day Moving Average of $55.00

March 8, 2024 | markets.businessinsider.com

Strong Buy Recommendation on Verona Pharma Backed by Positive Phase III Results and Robust Commercial Strategy

April 17, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

There are three basic steps to building the Ultimate Dividend Portfolio. Step #1 is to Get The High Yields! So an index fund like the SPY, paying only 1.5% a year, isn’t going to cut it. But a company like Altria Group (MO) will.

March 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed on Verona Pharma Ahead of Ensifentrine’s Expected FDA Approval and Strong Financial Standing

February 1, 2024 | markets.businessinsider.com

Michael Austwick Joins Verona Pharma as Non-Executive Director

January 3, 2024 | markets.businessinsider.com

BTIG Keeps Their Buy Rating on Verona Pharma (VRNA)

January 2, 2024 | msn.com

Verona Pharma enters upto $400M debt facility

January 1, 2024 | markets.businessinsider.com

BTIG Reaffirms Their Buy Rating on Verona Pharma (VRNA)

April 17, 2024 | DTI (Ad)

This company has increased its dividend every year for 54 years

November 3, 2023 | markets.businessinsider.com

Buy Rating for Verona Pharma: Strong Potential of Ensifentrine, Attractive Entry Point and Solid Financials

See More Headlines

Receive VRP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verona Pharma plc (VRP.L) and its competitors with MarketBeat's FREE daily newsletter.

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.